New York Genome Center

A breakthrough study by grantee New York Genome Center reveals new details about bladder cancer.

Big news today! Our group at New York Genome Center, in collaboration with Bishoy Morris Faltas at Weill Cornell Medicine, has published a significant study. We sequenced 77 tumor samples from bladder cancer patients, investigating the impact of APOBEC mutations and CCND1 amplification as extrachromosomal DNA. Grateful to all contributors! Read more about our findings on "The interplay of mutagenesis and ecDNA in shaping urothelial cancer evolution" here: https://lnkd.in/duMYMG_m and https://lnkd.in/dwXZQXKE #Research #CancerStudy #Collaboration #Genomics 🧬🔬

Scientists from the CDI were honored to present at a wide-ranging talk on cancer treatments of the future at the New York Genome Center on Oct. 1. The talks were presented as part of the New York Cancer Genomics Research Network Meeting. The moderator was Piero Dalerba, M.D., associate member of the CDI, whose work focuses on the discovery of biomarkers that are predictive of tumor response to anti-neoplastic drugs. Dalerba introduced talks by: Alvin Makohon-Moore, Ph.D., assistant member of the CDI; Benjamin Tycko, M.D., Ph.D., member of the CDI; and Hai-Hui (Howard) Xue, M.D., Ph.D, member of the CDI. The talks focused on their respective realms of expertise. Makohon-Moore presented on the experimental evolution of cancer in bioreactors in his lab; Tycko explained the value of using CRISPR as a research tool to home in on functional genetic variants that produce epigenetic changes, as a key adjunct to genome-wide disease association studies; and Xue spoke of immunological response in T cells and their effects in cancer development and potential treatments. Bravo to these scientists! #discovery #dna #cancer #science (Photo: NYGC)

Grantee New York Genome Center has produced a new tool that shows how tumor cells “shape-shift” as they become more aggressive and resistant to treatment.

We're in HIGH gear for Breast Cancer Awareness month! Stay tuned for some highlights of our team's activities, including the The Breast Cancer Research Foundation annual summit, the American Cancer Society #VOICES events, the 5th Annual Weill Cornell Medicine #BreastHealthDisparities #BHD2024 AND MORE --- including the planned launch of a new data portal with the New York Genome Center!

A powerful new analytical tool is providing scientists with unprecedented details of how tumor cells “shape-shift” to become more aggressive and untreatable. A tumor cell shape-shifts, called "plasticity," by changing its cell type or state, which alters its pattern of activity and sometimes its appearance. This changeability is a characteristic of cancer that leads to diverse tumor-cell populations and ultimately the emergence of cell types that spread or resist treatment. Using a new tool to quantify the plasticity in samples of tumor cells, researchers were able to identify, for example, a key transitional cell state in glioblastoma, the most common form of brain cancer. Researchers, led by Dr. Dan Landau of Weill Cornell Medicine and New York Genome Center, and Weill Cornell Medicine's Dr. Joshua Schiffman, Dr. Tamara Prieto, and student Andrew D’Avino, call their new tool “Phylogenetic Analysis of Trait Heritability,” or PATH. Full story: https://bit.ly/3ZwlKZO

Don't forget! Applications for our Early Career Development (post-bacc training) Program will close on October 1, 2024 at 11:59 PM EST. If interested in applying, click the link below for more information!

Congratulations to Zoé Butti, a postdoc in Hemali Phatnani's lab, for being named one of five 2024 Safenowitz Fellows through The ALS Association! Learn more about Dr. Butti's work by following the link below:

Researchers from grantee the New York Genome Center propose a framework built on blockchain that allows immutable storage, querying, and analysis of clinical and genetic data.